Rationale for haploinsufficiency correction therapy in neurofibromatosis type 1

Abstract

Neurofibromatosis type 1 (NF1) is a genetic disorder with a wide range of manifestations and severity. Currently, the few available NF1 treatments target specific manifestations, with no available therapies targeted to correct the underlying driver of all NF1 manifestations. Evidence supports that haploinsufficiency in NF1 caused by a decreased amount of wild-type (WT) neurofibromin in all NF1^+/- cells directly causes or facilitates a range of NF1 manifestations. Consequently, NF1 haploinsufficiency correction therapy (NF1-HCT) represents a potentially effective approach to treat some NF1 manifestations. NF1-HCT would normalize the level of WT neurofibromin in all NF1-haploinsufficient cells, including those integral to the NF1 phenotype such as Schwann cells (SCs), melanocytes, neurons, bone cells, and cells of the tumor microenvironment. This would correct altered cellular signaling pathways and, in turn, restore normal function to cells with a retained WT allele. NF1-HCT will not restore WT neurofibromin in NF1^-/- cells; however, by restoring function in the surrounding NF1^+/- microenvironment cells, NF1-HCT is predicted to have a beneficial effect on NF1^-/- cells. NF1-HCT is expected to have a clinical effect in some NF1 manifestations, as follows: (i) prevention, or delay of onset, of potential manifestations; and (ii) reversal, or halting/slowing progression, of established manifestations. This review describes the rationale for NF1-HCT, including specific NF1 considerations (e.g., NF1 clinical phenotype, neurofibromin function/regulation, NF1 mutational spectrum, genotype-phenotype correlation, and the impact of haploinsufficiency in NF1), HCT in other haploinsufficient diseases, potential NF1-HCT drug treatment strategies, and the potential advantages/challenges of NF1-HCT.

Keywords

Neurofibromatosis type 1 / neurofibromin / NF1 / haploinsufficiency / treatment

References

[1] FriedmanJM. Neurofibromatosis 1. In: Adam M, Ardinger H, et al., editors. Gene reviews. Seattle: University of Washington; 2019. p. 1-45. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1109/ [Last accessed on 21 Oct 2022]

[2] EvansDG,GiblinC.Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service.Am J Med Genet A2010;152A:327-32

[3] LammertM,KluweL.Prevalence of neurofibromatosis 1 in German children at elementary school enrollment.Arch Dermatol2005;141:71-4

[4] UusitaloE,KallionpääRA.Distinctive cancer associations in patients with neurofibromatosis type 1.J Clin Oncol2016;34:1978-86

[5] YangFC,RoblingAG.Hyperactivation of p21ras and PI3K cooperate to alter murine and human neurofibromatosis type 1-haploinsufficient osteoclast functions.J Clin Invest2006;116:2880-91 PMCID:PMC1616197

[6] RhodesSD,DongR.Nf1 haploinsufficiency alters myeloid lineage commitment and function, leading to deranged skeletal homeostasis.J Bone Miner Res2015;30:1840-51 PMCID:PMC5441523

[7] ZhuY,CharnayP,ParadaLF.Neurofibromas in NF1: Schwann cell origin and role of tumor environment.Science2002;296:920-2 PMCID:PMC3024710

[8] LiaoCP,BrosseauJP.Contributions of inflammation and tumor microenvironment to neurofibroma tumorigenesis.J Clin Invest2018;128:2848-61 PMCID:PMC6025974

[9] ChenZ,BrosseauJP.Spatiotemporal loss of NF1 in Schwann Cell Lineage Leads to Different Types of Cutaneous Neurofibroma Susceptible to Modification by the Hippo Pathway.Cancer Discov2019;9:114-29 PMCID:PMC6328325

[10] StansfieldBK,MaliR.Heterozygous inactivation of the Nf1 gene in myeloid cells enhances neointima formation via a rosuvastatin-sensitive cellular pathway.Hum Mol Genet2013;22:977-88 PMCID:PMC3561913

[11] LasaterEA,MeadLE.Nf1^+/- mice have increased neointima formation via hyperactivation of a Gleevec sensitive molecular pathway.Hum Mol Genet2008;17:2336-44 PMCID:PMC2733812

[12] LiF,SmileyLC.Neurofibromin-deficient myeloid cells are critical mediators of aneurysm formation in vivo.Circulation2014;129:1213-24 PMCID:PMC3960343

[13] SilvaAJ,MarowitzZ.A mouse model for the learning and memory deficits associated with neurofibromatosis type I.Nat Genet1997;15:281-4

[14] CuiY,MurphyGG.Neurofibromin regulation of ERK signaling modulates GABA release and learning.Cell2008;135:549-60 PMCID:PMC2673196

[15] CostaRM,KoganJH.Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1.Nature2002;415:526-30

[16] LiW,KushnerSA.The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1.Curr Biol2005;15:1961-7

[17] BajenaruML,HedrickNM,ParadaLF.Astrocyte-specific inactivation of the neurofibromatosis 1 gene (NF1) is insufficient for astrocytoma formation.Mol Cell Biol2002;22:5100-13 PMCID:PMC139771

[18] YapYS,OngCK.The NF1 gene revisited - from bench to bedside.Oncotarget2014;5:5873-92 PMCID:PMC4171599

[19] HymanSL,NorthKN.The nature and frequency of cognitive deficits in children with neurofibromatosis type 1.Neurology2005;65:1037-44

[20] AkbarniaBA,BeckmanE.Prevalence of scoliosis in neurofibromatosis.Spine1992;17:S244-8

[21] JaremkoJL,TorrianiM.Whole-body MRI in neurofibromatosis: incidental findings and prevalence of scoliosis.Skeletal Radiol2012;41:917-23

[22] HoltJF.1977 Edward B. D. Neuhauser lecture: neurofibromatosis in children.AJR Am J Roentgenol1978;130:615-39

[23] MillerDT,SchorryE,ViskochilD.Council on GeneticsAmerican College of Medical Genetics and GenomicsHealth supervision for children with neurofibromatosis type 1.Pediatrics2019;143:e20190660

[24] PeltonenS.Clinical diagnosis and atypical forms of NF1. In: Upadhyaya M, Cooper DN, editors. Neurofibromatosis type 1: molecular and cellular biology. Oxford: Bios Scientific; 2012. p. 17-30.

[25] MautnerVF.Value of whole body MRI in patients with NF1. In: Upadhyaya M, Cooper DN, editors. Neurofibromatosis type 1: molecular and cellular biology. Oxford: Bios Scientific; 2012. p. 83-91.

[26] RiccardiVM.Von Recklinghausen neurofibromatosis.N Engl J Med1981;305:1617-27

[27] FernerRE. Clinical aspects of neurofibromatosis 1. In: Upadhyaya M, Cooper DN, editors. Neurofibromatosis type 1: from genotype to phenotype. Oxford: Bios Scientific; 1998. p. 21-38.

[28] EastonDF,HusonSM.An analysis of variation in expression of neurofibromatosis (NF) type 1 (NF1): evidence for modifying genes.Am J Hum Genet1993;53:305-13 PMCID:PMC1682337

[29] RieleyMB,ViskochilDH,MartinLJ.Variable expression of neurofibromatosis 1 in monozygotic twins.Am J Med Genet A2011;155A:478-85

[30] MessiaenL.NF1 germline and somatic mosaicism. In: Upadhyaya M, Cooper D, editors. Neurofibromatosis type 1: molecular and cellular biology. Berlin Heidelberg: Springer-Verlag; 2012. p. 151-72.

[31] García-RomeroMT,Lara-CorralesI.Mosaic neurofibromatosis type 1: a systematic review.Pediatr Dermatol2016;33:9-17

[32] WalkerJA.Emerging therapeutic targets for neurofibromatosis type 1.Expert Opin Ther Targets2018;22:419-37 PMCID:PMC7017752

[33] PiovesanA,VitaleL,PelleriMC.Human protein-coding genes and gene feature statistics in 2019.BMC Res Notes2019;12:315 PMCID:PMC6549324

[34] NCBI. Available from: https://www.ncbi.nlm.nih.gov/books/NBK7273/ [Last accessed on 21 Oct 2022]

[35] Kehrer-SawatzkiH,CooperDN.Emerging genotype-phenotype relationships in patients with large NF1 deletions.Hum Genet2017;136:349-76 PMCID:PMC5370280

[36] DanglotG,FauvetD,KujasM.Neurofibromatosis 1 (NF1) mRNAs expressed in the central nervous system are differentially spliced in the 5’ part of the gene.Hum Mol Genet1995;4:915-20

[37] GeistRT.Expression of a developmentally-regulated neuron-specific isoform of the neurofibromatosis 1 (NF1) gene.Neuroscience Letters1996;211:85-8

[38] KaufmannD,KennerO.The N-terminal splice product NF1-10a-2 of the NF1 gene codes for a transmembrane segment.Biochem Biophys Res Commun2002;294:496-503

[39] NishiT,OkaK.Differential expression of two types of the neurofibromatosis type 1 ( NF1) gene transcripts related to neuronal differentiation.Oncogene1991;1:1555-9

[40] SuzukiY,KayamaT,ShibaharaS.Brain tumors predominantly express the neurofibromatosis type 1 gene transcripts containing the 63 base insert in the region coding for GTPase activating protein-related domain.Biochem Biophys Res Commun1991;181:955-61

[41] GutmannD,WrightD.Expression of the neurofibromatosis 1 (NF1) isoforms in developing and adult rat tissues.Cell Growth Differ1995;6:315-23

[42] ScheffzekK,WiesmüllerL.Structural analysis of the GAP-related domain from neurofibromin and its implications.EMBO J1998;17:4313-27 PMCID:PMC1170765

[43] BallesterR,BoguskiM.The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins.Cell1990;63:851-9

[44] MartinGA,BollagG.The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21.Cell1990;63:843-9

[45] BosJL,WittinghoferA.GEFs and GAPs: critical elements in the control of small G proteins.Cell2007;129:865-77

[46] MarchukDA,TavakkolR.cDNA cloning of the type 1 neurofibromatosis gene: complete sequence of the NF1 gene product.Genomics1991;11:931-40

[47] AndersenLB,MarchukDA.A conserved alternative splice in the von Recklinghausen neurofibromatosis (NF1) gene produces two neurofibromin isoforms, both of which have GTPase-activating protein activity.Mol Cell Biol1993;13:487-95 PMCID:PMC358928

[48] YunoueS,FukunagaK.Neurofibromatosis type I tumor suppressor neurofibromin regulates neuronal differentiation via its GTPase-activating protein function toward Ras.J Biol Chem2003;278:26958-69

[49] DastonMM.Neurofibromin, a predominantly neuronal GTPase activating protein in the adult, is ubiquitously expressed during development.Dev Dyn1992;195:216-26

[50] DastonMM,NordlundM,NissenLM.The protein product of the neurofibromatosis type 1 gene is expressed at highest abundance in neurons, Schwann cells, and oligodendrocytes.Neuron1992;8:415-28

[51] SimanshuDK,McCormickF.RAS proteins and their regulators in human disease.Cell2017;170:17-33 PMCID:PMC5555610

[52] StoweIB,StoweTR.A shared molecular mechanism underlies the human rasopathies Legius syndrome and Neurofibromatosis-1.Genes Dev2012;26:1421-6 PMCID:PMC3403010

[53] SherekarM,GhirlandoR.Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.J Biol Chem2020;295:1105-19 PMCID:PMC6983858

[54] NaschbergerA,RuppB.The structure of neurofibromin isoform 2 reveals different functional states.Nature2021;599:315-9 PMCID:PMC8580823

[55] BrannanCI,VogelKS.Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues.Genes Dev1994;8:1019-29

[56] JacksT,SchmittEM,BernardsA.Tumour predisposition in mice heterozygous for a targeted mutation in Nf1.Nat Genet1994;7:353-61

[57] WeeP.Epidermal growth factor receptor cell proliferation signaling pathways.Cancers2017;9:52 PMCID:PMC5447962

[58] HobbsGA,RossmanKL.RAS isoforms and mutations in cancer at a glance.J Cell Sci2016;129:1287-92 PMCID:PMC4869631

[59] RauenKA.The RASopathies.Annu Rev Genomics Hum Genet2013;14:355-69 PMCID:PMC4115674

[60] JindalGA,BurdineRD,ShvartsmanSY.RASopathies: unraveling mechanisms with animal models.Dis Model Mech2015;8:769-82 PMCID:PMC4527292

[61] PhilpottC,FraylingIM,UpadhyayaM.The NF1 somatic mutational landscape in sporadic human cancers.Hum Genomics2017;11:13 PMCID:PMC5480124

[62] WallaceMD,ShenL.Comparative oncogenomics implicates the neurofibromin 1 gene (NF1) as a breast cancer driver.Genetics2012;192:385-96 PMCID:PMC3454871

[63] SeeWL,MukherjeeJ,PieperRO.Sensitivity of glioblastomas to clinically available MEK inhibitors is defined by neurofibromin 1 deficiency.Cancer Res2012;72:3350-9 PMCID:PMC4128256

[64] LauchleJO,LeDT.Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras.Nature2009;461:411-4 PMCID:PMC4119783

[65] deBruin EC,WarnePH.Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer.Cancer Discov2014;4:606-19 PMCID:PMC4011693

[66] PyC,KreutzfeldtM,DietrichPY.Response of NF1-Mutated Melanoma to an MEK Inhibitor.JCO Precis Oncol2018;2:1-11

[67] ByronSA,HalperinRF.Prospective feasibility trial for genomics-informed treatment in recurrent and progressive glioblastoma.Clin Cancer Res2018;24:295-305 PMCID:PMC7516926

[68] OmraniA,MientjesE.HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.Mol Psychiatry2015;20:1311-21 PMCID:PMC5603719

[69] TongJ,ZhuY,ZhongY.Neurofibromin regulates G protein-stimulated adenylyl cyclase activity.Nat Neurosci2002;5:95-6

[70] GuoHF,HannanF,ZhongY.Requirement of Drosophila NF1 for activation of adenylyl cyclase by PACAP38-like neuropeptides.Science1997;276:795-8

[71] GuoHF,HannanF,ZhongY.A neurofibromatosis-1-regulated pathway is required for learning in Drosophila.Nature2000;403:895-8

[72] HannanF,TongJJ,NurnbergP.Effect of neurofibromatosis type I mutations on a novel pathway for adenylyl cyclase activation requiring neurofibromin and Ras.Hum Mol Genet2006;15:1087-98 PMCID:PMC1866217

[73] HoIS,GuoHF,ZhongY.Distinct functional domains of neurofibromatosis type 1 regulate immediate versus long-term memory formation.J Neurosci2007;27:6852-7 PMCID:PMC6672704

[74] WalkerJA,McKenneyPT.Reduced growth of Drosophila neurofibromatosis 1 mutants reflects a non-cell-autonomous requirement for GTPase-Activating Protein activity in larval neurons.Genes Dev2006;20:3311-23 PMCID:PMC1686607

[75] TheI,CowleyGS.Rescue of a Drosophila NF1 mutant phenotype by protein kinase A.Science1997;276:791-4

[76] HegedusB,LeeDY,LiJ.Neurofibromin regulates somatic growth through the hypothalamic-pituitary axis.Hum Mol Genet2008;17:2956-66 PMCID:PMC2596853

[77] SzudekJ,FriedmanJM.Growth in North American white children with neurofibromatosis 1 (NF1).J Med Genet2000;37:933-8 PMCID:PMC1734506

[78] ElefteriouF,SchindelerA.Skeletal abnormalities in neurofibromatosis type 1: approaches to therapeutic options.Am J Med Genet A2009;149A:2327-38

[79] BrownJA,WhiteCR.Reduced striatal dopamine underlies the attention system dysfunction in neurofibromatosis-1 mutant mice.Hum Mol Genet2010;19:4515-28 PMCID:PMC2957316

[80] Diggs-AndrewsKA,IzumiY,WozniakDF.Dopamine deficiency underlies learning deficits in neurofibromatosis-1 mice.Ann Neurol2013;73:309-15 PMCID:PMC3608728

[81] PatrakitkomjornS,MorikawaT.Neurofibromatosis type 1 (NF1) tumor suppressor, neurofibromin, regulates the neuronal differentiation of PC12 cells via its associating protein, CRMP-2.J Biol Chem2008;283:9399-413

[82] BellampalliSS.Towards a neurobiological understanding of pain in neurofibromatosis type 1: mechanisms and implications for treatment.Pain2019;160:1007-18 PMCID:PMC6478401

[83] FadhlullahSFB,YeoJYT.Pathogenic mutations in neurofibromin identifies a leucine-rich domain regulating glioma cell invasiveness.Oncogene2019;38:5367-80 PMCID:PMC6755990

[84] ShapiraS,FriedmanE,SteinR.The tumor suppressor neurofibromin confers sensitivity to apoptosis by Ras-dependent and Ras-independent pathways.Cell Death Differ2007;14:895-906

[85] SummersMA,PayneJM,NorthKN.Skeletal muscle and motor deficits in neurofibromatosis type 1.J Musculoskelet Neuronal Interact2015;15:161-70 PMCID:PMC5133719

[86] CornettKM,RoseKJ.Muscle weakness in children with neurofibromatosis type 1.Dev Med Child Neurol2015;57:733-6

[87] PinhoRS,PaschoalJKSF.Migraine is frequent in children and adolescents with neurofibromatosis type 1.Pediatr Int2014;56:865-7

[88] LicisAK,GaoF.Prevalence of sleep disturbances in children with neurofibromatosis type 1.J Child Neurol2013;28:1400-5 PMCID:PMC3805763

[89] LeschzinerGD,FernerRE.Sleep disturbance as part of the neurofibromatosis type 1 phenotype in adults.Am J Med Genet A2013;161A:1319-22

[90] LammertM,RothHJ.Vitamin D deficiency associated with number of neurofibromas in neurofibromatosis 1.J Med Genet2006;43:810-3 PMCID:PMC2563168

[91] TuckerT,HartmannM.Bone health and fracture rate in individuals with neurofibromatosis 1 (NF1).J Med Genet2009;46:259-65

[92] StevensonDA,CareyJC.Pediatric 25-hydroxyvitamin D concentrations in neurofibromatosis type 1.J Pediatr Endocrinol Metab2011;24:169-74 PMCID:PMC3246508

[93] SouzaMario Bueno L,AguiarE.Vitamin D status and VDR genotype in NF1 patients: a case-control study from Southern Brazil.Int J Endocrinol2015;2015:402838 PMCID:PMC4487339

[94] HockettCW,HusonSM.Vitamin D status and muscle function in children with neurofibromatosis type 1 (NF1).J Musculoskelet Neuronal Interact2013;13:111-9

[95] JouhilahtiEM,HeapeAM.The pathoetiology of neurofibromatosis 1.Am J Pathol2011;178:1932-9 PMCID:PMC3081157

[96] PaschouM.Neurofibromin 1 is a miRNA target in neurons.PLoS One2012;7:e46773 PMCID:PMC3462785

[97] ZouMX,SadikovicB,YeeSP.Characterization of functional elements in the neurofibromatosis (NF1) proximal promoter region.Oncogene2004;23:330-9

[98] YangG,vande Locht L.Transcriptional repression of the Neurofibromatosis-1 tumor suppressor by the t(8;21) fusion protein.Mol Cell Biol2005;25:5869-79 PMCID:PMC1168824

[99] LuH,PangQ.MiR-27a-3p/miR-27b-3p promotes neurofibromatosis type 1 via targeting of NF1.J Mol Neurosci2021;71:2353-63

[100] CichowskiK,JardimM,JacksT.Dynamic regulation of the Ras pathway via proteolysis of the NF1 tumor suppressor.Genes Dev2003;17:449-54 PMCID:PMC195996

[101] McGillicuddyLT,HollsteinPE.Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis.Cancer Cell2009;16:44-54 PMCID:PMC2897249

[102] HollsteinPE.Identifying the Ubiquitin Ligase complex that regulates the NF1 tumor suppressor and Ras.Cancer Discov2013;3:880-93 PMCID:PMC3881282

[103] MessiaenL.NF1 mutational spectrum. In: Kaufmann D, editor. Neurofibromatoses. Basel: KARGER; 2008. p. 63-77.

[104] KoczkowskaM,CallensT.Genotype-phenotype correlation in NF1: evidence for a more severe phenotype associated with missense mutations affecting NF1 codons 844-848.Am J Hum Genet2018;102:69-87 PMCID:PMC5777934

[105] ValeroMC,Hernández-ImazE.A highly sensitive genetic protocol to detect NF1 mutations.J Mol Diagn2011;13:113-22 PMCID:PMC3128626

[106] KurosakiT,MaquatLE.Quality and quantity control of gene expression by nonsense-mediated mRNA decay.Nat Rev Mol Cell Biol2019;20:406-20 PMCID:PMC6855384

[107] Ben-ShacharS,HalleviH.Increased rate of missense/in-frame mutations in individuals with NF1-related pulmonary stenosis: a novel genotype-phenotype correlation.Eur J Hum Genet2013;21:535-9 PMCID:PMC3641387

[108] RuggieriM,SpaliceA.The natural history of spinal neurofibromatosis: a critical review of clinical and genetic features.Clin Genet2015;87:401-10

[109] MartinMC,YuJ.Small molecule approaches for targeting the polycomb repressive complex 2 (PRC2) in cancer.J Med Chem2020;63:15344-70

[110] YoungL,HanS. Severe phenotype-linked NF1 substitution mutations in codons 844-848 of neurofibromin act in a dominant negative manner by destabilizing wild-type protein. In: NF Conference Book. Children’s Tumor Foundation; 2020. p. 23. Available from: https://www.ctf.org/images/uploads/documents/2020_NF_Conference_Book.pdf [Last accessed on 21 Oct 2022]

[111] LongA,LiuJ.Analysis of patient-specific NF1 variants leads to functional insights for Ras signaling that can impact personalized medicine.Hum Mutat2022;43:30-41

[112] PasmantE,SpurlockG.Members of the NF France NetworkNF1 microdeletions in neurofibromatosis type 1: from genotype to phenotype.Hum Mutat2010;31:E1506-18

[113] BarreaC,BulkS,MissonJP.Phenotype-genotype correlation in children with neurofibromatosis type 1.Neuropediatrics2018;49:180-4

[114] KoczkowskaM,ChenY.Clinical spectrum of individuals with pathogenic NF1 missense variants affecting p.Met1149, p.Arg1276, and p.Lys1423: genotype-phenotype study in neurofibromatosis type 1.Hum Mutat2020;41:299-315 PMCID:PMC6973139

[115] UpadhyayaM,DaviesM.An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in exon 17 of the NF1 gene (c.2970-2972 delAAT): evidence of a clinically significant NF1 genotype-phenotype correlation.Am J Hum Genet2007;80:140-51 PMCID:PMC1785321

[116] KoczkowskaM,GomesA.Expanding the clinical phenotype of individuals with a 3-bp in-frame deletion of the NF1 gene (c.2970_2972del): an update of genotype-phenotype correlation.Genet Med2019;21:867-76 PMCID:PMC6752285

[117] RojnueangnitK,GomesA.High incidence of noonan syndrome features including short stature and pulmonic stenosis in patients carrying NF1 missense mutations affecting p.Arg1809: genotype-phenotype correlation.Hum Mutat2015;36:1052-63 PMCID:PMC5049609

[118] KnudsonAG Jr.Mutation and cancer: statistical study of retinoblastoma.Proc Natl Acad Sci U S A1971;68:820-3 PMCID:PMC389051

[119] MellertK,LüdekeM.Restoring functional neurofibromin by protein transduction.Sci Rep2018;8:6171 PMCID:PMC5906691

[120] LasaterEA,BesslerWK.Genetic and cellular evidence of vascular inflammation in neurofibromin-deficient mice and humans.J Clin Invest2010;120:859-70 PMCID:PMC2827964

[121] StevensonDA. Molecular basis of bone abnormalities in NF1. In: Upadhyaya M, Cooper DN, editors. Molecular and cellular biology of neurofibromatosis type 1. Heidelberg: Springer Verlag; 2012. p. 327-40. Available from: https://link.springer.com/book/10.1007/978-3-642-32864-0 [Last accessed on 21 Oct 2022]

[122] StansfieldBK,ConwaySJ. Molecular basis of cardiovascular abnormalities in NF1. In: Upadhyaya M, Cooper DN, editors. Molecular and cellular biology of neurofibromatosis type 1. Heidelberg: Springer Verlag; 2012. p. 353-66. Available from: https://link.springer.com/book/10.1007/978-3-642-32864-0 [Last accessed on 21 Oct 2022]

[123] YuX,PotterOL.Neurofibromin and its inactivation of Ras are prerequisites for osteoblast functioning.Bone2005;36:793-802

[124] StevensonDA,ViskochilDH.Evidence of increased bone resorption in neurofibromatosis type 1 using urinary pyridinium crosslink analysis.Pediatr Res2008;63:697-701 PMCID:PMC3235045

[125] SchindelerA,HarryL.Models of tibial fracture healing in normal and Nf1-deficient mice.J Orthop Res2008;26:1053-60

[126] SchindelerA,YuNY.Distal tibial fracture repair in a neurofibromatosis type 1-deficient mouse treated with recombinant bone morphogenetic protein and a bisphosphonate.J Bone Joint Surg Br2011;93:1134-9

[127] RasmussenSA,FriedmanJM.Mortality in neurofibromatosis 1: an analysis using U.S. death certificates.Am J Hum Genet2001;68:1110-8 PMCID:PMC1226092

[128] FriedmanJM,EpsteinJA.Cardiovascular disease in neurofibromatosis 1: report of the NF1 Cardiovascular Task Force.Genet Med2002;4:105-11

[129] OderichGS,BowerTC.Vascular abnormalities in patients with neurofibromatosis syndrome type I: clinical spectrum, management, and results.J Vasc Surg2007;46:475-84

[130] AnastasakiC,MessiaenLM.Elucidating the impact of neurofibromatosis-1 germline mutations on neurofibromin function and dopamine-based learning.Hum Mol Genet2015;24:3518-28 PMCID:PMC4553714

[131] JentarraGM,OlfersS,SaffenDM.Skewed allele-specific expression of the NF1 gene in normal subjects: a possible mechanism for phenotypic variability in neurofibromatosis type 1.J Child Neurol2012;27:695-702

[132] HoffmeyerS,GriesserJ,NürnbergP.On unequal allelic expression of the neurofibromin gene in neurofibromatosis type 1.Hum Mol Genet1995;4:1267-72

[133] MoloshAI,SpenceJP.Social learning and amygdala disruptions in Nf1 mice are rescued by blocking p21-activated kinase.Nat Neurosci2014;17:1583-90 PMCID:PMC4213300

[134] YangFC,ChenS.Neurofibromin-deficient Schwann cells secrete a potent migratory stimulus for Nf1+/- mast cells.J Clin Invest2003;112:1851-61 PMCID:PMC296994

[135] YangFC,ChenS.Nf1-dependent tumors require a microenvironment containing Nf1+/- and c-kit-dependent bone marrow.Cell2008;135:437-48 PMCID:PMC2788814

[136] BajenaruML,PerryA.Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity.Cancer Res2003;63:8573-7

[137] RadomskaKJ,GressetA.Cellular origin, tumor progression, and pathogenic mechanisms of cutaneous neurofibromas revealed by mice with Nf1 knockout in boundary cap cells.Cancer Discov2019;9:130-47

[138] BrosseauJP,WangY.NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.Nat Commun2018;9:5014 PMCID:PMC6258697

[139] Kehrer-SawatzkiH,CallensT.Identification of large NF1 duplications reciprocal to NAHR-mediated type-1 NF1 deletions.Hum Mutat2014;35:1469-75

[140] MolesKJ,GedelaS.NF1 microduplications: identification of seven nonrelated individuals provides further characterization of the phenotype.Genet Med2012;14:508-14

[141] GrisartB,VidrequinS.NF1 microduplication first clinical report: association with mild mental retardation, early onset of baldness and dental enamel hypoplasia?.Eur J Hum Genet2008;16:305-11

[142] UmanoffH,PellicerA.The murine N-ras gene is not essential for growth and development.Proc Natl Acad Sci U S A1995;92:1709-13 PMCID:PMC42589

[143] EstebanLM,Fernández-SalgueroP.Targeted genomic disruption of H-ras and N-ras, individually or in combination, reveals the dispensability of both loci for mouse growth and development.Mol Cell Biol2001;21:1444-52 PMCID:PMC86690

[144] KoeraK,NakaoK.K-ras is essential for the development of the mouse embryo.Oncogene1997;15:1151-9

[145] NakamuraK,NakaoK.Partial functional overlap of the three ras genes in mouse embryonic development.Oncogene2008;27:2961-8

[146] MatharuN,TamuraS.CRISPR-mediated activation of a promoter or enhancer rescues obesity caused by haploinsufficiency.Science2019;363:eaau0629 PMCID:PMC6570489

[147] DangVT,MarcosAE.Identification of human haploinsufficient genes and their genomic proximity to segmental duplications.Eur J Hum Genet2008;16:1350-7

[148] DelaneyJR,WillisKM.Haploinsufficiency networks identify targetable patterns of allelic deficiency in low mutation ovarian cancer.Nat Commun2017;8:14423 PMCID:PMC5316854

[149] LeenWG,VerbeekMM.Glucose transporter-1 deficiency syndrome: the expanding clinical and genetic spectrum of a treatable disorder.Brain2010;133:655-70

[150] TangM,DeVivo DC.Therapeutic strategies for glucose transporter 1 deficiency syndrome.Ann Clin Transl Neurol2019;6:1923-32 PMCID:PMC6764625

[151] BrunklausA.Dravet syndrome--from epileptic encephalopathy to channelopathy.Epilepsia2014;55:979-84

[152] RabieeB,ShenX.Gene dosage manipulation alleviates manifestations of hereditary PAX6 haploinsufficiency in mice.Sci Transl Med2020;12:eaaz4894

[153] TangM,RuedaCB.Brain microvasculature defects and Glut1 deficiency syndrome averted by early repletion of the glucose transporter-1 protein.Nat Commun2017;8:14152 PMCID:PMC5263887

[154] ColasanteG,BruscoS.dCas9-based scn1a gene activation restores inhibitory interneuron excitability and attenuates seizures in dravet syndrome mice.Mol Ther2020;28:235-53 PMCID:PMC6952031

[155] HuangHS,MabbAM.Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons.Nature2011;481:185-9 PMCID:PMC3257422

[156] HassonSA,WangC.Chemogenomic profiling of endogenous PARK2 expression using a genome-edited coincidence reporter.ACS Chem Biol2015;10:1188-97

[157] LipinskiCA,DominyBW.Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.Adv Drug Deliv Rev2001;46:3-26

[158] LeesonPD.The influence of drug-like concepts on decision-making in medicinal chemistry.Nat Rev Drug Discov2007;6:881-90

[159] LiQ.Mechanisms of action for small molecules revealed by structural biology in drug discovery.Int J Mol Sci2020;21:5262 PMCID:PMC7432558

[160] NgoHX.What are the drugs of the future?.Medchemcomm2018;9:757-8 PMCID:PMC6072476

[161] SunW,SimeonovA.Drug discovery and development for rare genetic disorders.Am J Med Genet A2017;173:2307-22 PMCID:PMC5662129

[162] CrostonGE.The utility of target-based discovery.Expert Opin Drug Discov2017;12:427-9

[163] MiddletonPG,DřevínekP.VX17-445-102 Study GroupElexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single phe508del allele.N Engl J Med2019;381:1809-19 PMCID:PMC7282384

[164] ZhuPJ,CuiY.Activation of the ISR mediates the behavioral and neurophysiological abnormalities in Down syndrome.Science2019;366:843-9 PMCID:PMC7299149

[165] PorterBA,BratslavskyG.Structure and function of the nuclear receptor superfamily and current targeted therapies of prostate cancer.Cancers 2019;11:1852 PMCID:PMC6966469

[166] ZhengXS,ZhouHH.Genetic and genomic approaches to identify and study the targets of bioactive small molecules.Chem Biol2004;11:609-18

[167] HuynhDP,PulstSM.Differential expression and tissue distribution of type I and type II neurofibromins during mouse fetal development.Dev Biol1994;161:538-51

[168] GutmannDH,CollinsFS. Chapter 33 Expression of the neurofibromatosis type 1 (NF1) gene during mouse embryonic development. Gene expression in the central nervous system. Elsevier; 1995. p. 327-35.

[169] ShermanL,RatnerN.Neurofibromin: distribution, cell biology and role in neurofibromatosis type 1. In: Upadhyaya M, Cooper D, editors. Neurofibromatosis type 1 from genotype to phenotype. Oxford: Bios scientific; 1998. p. 113-26.

[170] RatnerN.A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor.Nat Rev Cancer2015;15:290-301 PMCID:PMC4822336

[171] OtisEM.Equivalent ages in mouse and human embryos.Anat Rec1954;120:33-63

[172] PatelA,DuanD.Design of AAV vectors for delivery of large or multiple transgenes.Methods Mol Biol2019;1950:19-33

[173] TrapaniI.Adeno-associated viral vectors as a tool for large gene delivery to the retina.Genes 2019;10:287 PMCID:PMC6523333

[174] BaiRY,TamAJ.Feasibility of using NF1-GRD and AAV for gene replacement therapy in NF1-associated tumors.Gene Ther2019;26:277-86 PMCID:PMC6588423

[175] Trovó-MarquiAB.Neurofibromin: a general outlook.Clin Genet2006;70:1-13

[176] GrossAM,DombiE.Selumetinib in children with inoperable plexiform neurofibromas.N Engl J Med2020;382:1430-42 PMCID:PMC7305659

[177] KallionpääRA,LeppävirtaJ.Haploinsufficiency of the NF1 gene is associated with protection against diabetes.J Med Genet2021;58:378-84 PMCID:PMC8142421